TABLE 1.
Histatin IC50s determined for a range of C. dubliniensis strains from different sources
| Yeast | Body site | Country of isolation | HIV status of patient | IC50 (mg/ml)
|
Source or reference | |
|---|---|---|---|---|---|---|
| Mean ± SDa (n) | Range | |||||
| C. dubliniensis | ||||||
| P0508 | Blood | Israel | − | 0.043 ± 0.016 (6) | 0.024-0.079 | This study |
| CD2081 | Oral cavity | Ireland | − | 0.055 ± 0.018 (3) | 0.040-0.082 | This study |
| CD51-IICb | Oral cavity | Ireland | + | 0.057 ± 0.032 (6) | 0.022-0.112 | 20 |
| CD36c | Oral cavity | Ireland | + | 0.072 ± 0.033 (3) | 0.048-0.119 | 36 |
| CM2d | Oral cavity | Australia | + | 0.075 ± 0.015 (5) | 0.054-0.099 | 20 |
| CD2092 | Oral | France | + | 0.092 ± 0.036 (3) | 0.050-0.140 | This study |
| CD2093 | Oral | France | + | 0.095 ± 0.019 (3) | 0.076-0.122 | This study |
| CD411 | Oral cavity | Ireland | + | 0.103 ± 0.026 (3) | 0.065-0.145 | 26 |
| P8679 | Retina | Israel | − | 0.190 ± 0.060 (6) | 0.130-0.079 | This study |
| CBS8501 | Blood | Holland | − | 0.191 ± 0.115 (6) | 0.088-0.440 | 19 |
| P9224 | Cornea | Israel | − | 0.196 ± 0.022 (6) | 0.170-0.230 | This study |
| C. albicans 132A | Oral cavity | Ireland | + | 0.096 ± 0.049 (6) | 0.028-0.152 | 9 |
a
Values shown are mean averages of several independent experiments (n) ± standard deviations. IC50 was determined as described in Materials and Methods.
b
CD51-IIC is an in vitro-generated fluconazole-resistant derivative of C. dubliniensis clinical isolate CD51-II, which is fluconazole susceptible.
c
CD36 is the C. dubliniensis type strain (36).
d
CM2 is a fluconazole-resistant clinical isolate; all the other isolates tested were fluconazole susceptible.